Nguyen, Bella Hai; Robinson, E; Arora, A; Ali, Sayed
Background: The introduction of anti-PD1 checkpoint inhibitors: pembrolizumab
and nivolumab has changed the treatment landscape of stage IV
melanoma. Clinical trials reported response rates between 21% and 32%.2
Grade 3-4 adverse events ranged between 5% and 14%.1,2 A single-center
experience of safety and efficacy of pembrolizumab, or nivolumab in treating
stage IV melanoma were analyzed in this presentation.
Methods: Records of patients from The Canberra Hospital between January
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.